BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11706400)

  • 1. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
    Dempke WC
    Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
    Caraglia M; Budillon A; Tagliaferri P; Marra M; Abbruzzese A; Caponigro F
    Curr Drug Targets; 2005 May; 6(3):301-23. PubMed ID: 15857290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of clinical trials of farnesyltransferase inhibitors.
    Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
    Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyl transferase inhibitors as anticancer agents.
    Haluska P; Dy GK; Adjei AA
    Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors.
    Sebti SM; Adjei AA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS inhibitors: potential for cancer therapeutics.
    Kloog Y; Cox AD
    Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl transferase inhibitors in myeloid malignancies.
    Lancet JE; Karp JE
    Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.